Webinar: AI’s role in shaping future therapeutics by LabX Media Group

Host Login

About This Webinar

There are countless medical conditions without effective therapeutic options. By using machine learning and artificial intelligence to understand the relationships between amino acid sequence, molecular structure, and protein function, researchers can unearth new therapeutic options to address unmet clinical needs. In this webinar brought to you by Thermo Fisher Scientific, Alex Snyder from Generate:Biomedicines will explore how rapidly advancing machine learning technology identifies novel therapeutic targets, optimizes drug design, and speeds up drug development.

Topics to be covered

• Filling critical gaps in medical treatment using AI technologies
• Synergistically integrating dry- and wet-lab approaches to accelerate drug development

Presenter

Alex Snyder, MD

Executive Vice President, Research and Development, Generate:Biomedicines

Alex Snyder is the executive vice president for research and development at Generate:Biomedicines. She is also a voluntary faculty member at Bellevue Hospital and New York University. She received her medical degree at Mount Sinai Medical School and completed an internal medicine residency at Mount Sinai Hospital and a medical oncology fellowship at Memorial Sloan Kettering Cancer Center. Upon completing her fellowship in 2014, she practiced oncology at Memorial Sloan Kettering Cancer Center. From 2018-2021, Snyder served as the head of translational oncology at Merk, where she conducted Merck-sponsored clinical trials across pipeline combination therapies at worldwide sites and led companion diagnostic strategies, biomarker programs, and quantitative pharmacology studies for oncology clinical trials. Prior to joining Generate:Biomedicines in 2022, Snyder worked with the private equity firm Two River, where she was responsible for setting the translational and clinical strategy for their portfolio of novel biotech companies. At Generate:Biomedicine, Snyder leverages her extensive clinical and scientific experience to help the company advance its generative AI pipeline of protein therapeutics to the clinical stage.